Education
About Us
Working with TipRanks
Follow Us
Cibus (CBUS)
NASDAQ:CBUS
CBUS Stock Chart & Stats
$3.68
-$0.23(-7.99%)
At close: 4:00 PM EST
$3.68
-$0.23(-7.99%)
Day’s Range― - ―
52-Week Range$1.09 - $4.19
Previous CloseN/A
Volume64.89K
Average Volume (3M)154.04K
Market Cap
$171.61M
Enterprise Value$384.04M
Total Cash (Recent Filing)$9.92M
Total Debt (Recent Filing)$267.96M
Price to Earnings (P/E)―
Beta3.00
Next Earnings
May 07, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding69,196,120
10 Day Avg. Volume164,630
30 Day Avg. Volume154,044
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)36.47
Price to Sales (P/S)218.79
P/FCF Ratio-15.56
Enterprise Value/Market Cap2.24
Enterprise Value/Revenue105.54
Enterprise Value/Gross Profit441.43
Enterprise Value/Ebitda-6.24
Forecast
1Y Price Target
$16.00Price Target Upside334.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.24
Revenue Forecast (FY)$8.06M
Bulls Say, Bears Say
Bulls Say
Commercialization TractionCompletion of pre-commercial pilot runs for two fermentation-based biofragrance products and multiple rice trait agreements across Latin America and the U.S. signal tangible early commercial momentum.
Intellectual PropertyEstablishment of a patenting expert group focused on NGT plant patenting may strengthen intellectual property protection and enhance the company's competitive position for its trait portfolio.
Operational EfficiencySequential improvement in the bottom line alongside company-wide cost-cutting and standardization efforts is reducing cash burn and improving financial resilience.
Bears Say
Financing RiskManagement's indication that additional capital will be needed in 2026 and the pursuit of large seed-company development partners underscores funding risk that could cause dilution or slow program progress if partnerships are not secured.
Regulatory RiskHerbicide tolerance traits classified as NGT-2 face authorization, traceability, and monitoring requirements similar to GMOs, which could delay approvals and limit market access.
Cibus News
CBUS FAQ
What was Cibus’s price range in the past 12 months?
Cibus lowest stock price was $1.09 and its highest was $4.19 in the past 12 months.
What is Cibus’s market cap?
Cibus’s market cap is $171.61M.
When is Cibus’s upcoming earnings report date?
Cibus’s upcoming earnings report date is May 07, 2026 which is in 44 days.
How were Cibus’s earnings last quarter?
Cibus released its earnings results on Mar 17, 2026. The company reported -$0.59 earnings per share for the quarter, missing the consensus estimate of -$0.352 by -$0.238.
Is Cibus overvalued?
According to Wall Street analysts Cibus’s price is currently Undervalued.
Does Cibus pay dividends?
Cibus does not currently pay dividends.
What is Cibus’s EPS estimate?
Cibus’s EPS estimate is -0.22.
How many shares outstanding does Cibus have?
Cibus has 69,196,120 shares outstanding.
What happened to Cibus’s price movement after its last earnings report?
Cibus reported an EPS of -$0.59 in its last earnings report, missing expectations of -$0.352. Following the earnings report the stock price went down -24.728%.
Which hedge fund is a major shareholder of Cibus?
Currently, no hedge funds are holding shares in CBUS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cibus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.00 (334.78% Upside)
$16.00 (334.78% Upside)
Hedge Fund Trend
Decreased
By 22.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 11.1%
Last 30 Days ▲ 17.1%
Last 30 Days ▲ 17.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.92%
12-Months-Change
Fundamentals
Return on Equity
-236.85%
Trailing 12-Months
Asset Growth
-12.86%
Trailing 12-Months
Company Description
Cibus
Cibus, Inc., a agricultural technology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. The company is based in San Diego, California.
CBUS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial positive progress on technology performance, regulatory milestones, customer engagements, and near-term commercialization plans (especially for rice and sustainable ingredients). Management also executed meaningful cost reductions and secured a $22.3M financing to extend runway. Major challenges remain: the company is still loss-making with a Q4 net loss widened ~23.6%, royalty interest expense is significant, collaboration revenue timing weighed on results, and cash runway extends only into late 2026 absent further revenue or financing. Overall, the call emphasized execution and upcoming catalysts (EU plenary vote, Interox definitive agreement, Latin America field results) that support momentum but also highlighted the need to convert progress into cash flow in the near term.View all CBUS earnings summariesCBUS Stock 12 Month Forecast
Average Price Target
$16.00
▲(334.78% Upside)
Technical Analysis
Ownership Overview
30.02% Insiders
7.68% Mutual Funds
2.79% Other Institutional Investors
56.72% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---